Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 4/2022

18-05-2022 | Sarcoidosis | Review Article

The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy

Authors: Julie H. Wu, Sotonye Imadojemu, Avrom S. Caplan

Published in: American Journal of Clinical Dermatology | Issue 4/2022

Login to get access

Abstract

Sarcoidosis is a multisystem disorder of unknown etiology characterized by accumulation of granulomas in affected tissue. Cutaneous manifestations are among the most common extrapulmonary manifestations in sarcoidosis and can lead to disfiguring disease requiring chronic therapy. In many patients, skin disease may be the first recognized manifestation of sarcoidosis, necessitating a thorough evaluation for systemic involvement. Although the precise etiology of sarcoidosis and the pathogenic mechanisms leading to granuloma formation, persistence, or resolution remain unclear, recent research has led to significant advances in our understanding of this disease. This article reviews recent advances in epidemiology, sarcoidosis clinical assessment with a focus on the dermatologist’s role, disease pathogenesis, and new therapies in use and under investigation for cutaneous and systemic sarcoidosis.
Literature
1.
Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, Muller-Quernheim J. Sarcoidosis. Nat Rev Dis Primers. 2019;5(1):45.PubMedCrossRef
2.
3.
Marcoval J, Mana J, Rubio M. Specific cutaneous lesions in patients with systemic sarcoidosis: relationship to severity and chronicity of disease. Clin Exp Dermatol. 2011;36(7):739–44.PubMedCrossRef
4.
Wanat KA, Rosenbach M. A practical approach to cutaneous sarcoidosis. Am J Clin Dermatol. 2014;15(4):283–97.PubMedCrossRef
5.
Drent M, Crouser ED, Grunewald J. Challenges of sarcoidosis and its management. N Engl J Med. 2021;385(11):1018–32.PubMedCrossRef
6.
Yamaguchi M, Hosoda Y, Sasaki R, Aoki K. Epidemiological study on sarcoidosis in Japan. Recent trends in incidence and prevalence rates and changes in epidemiological features. Sarcoidosis. 1989;6(2):138–46.PubMed
7.
Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ, Kurland LT. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol. 1986;123(5):840–5.PubMedCrossRef
8.
Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119–27.PubMed
9.
10.
Yanardag H, Pamuk ON, Karayel T. Cutaneous involvement in sarcoidosis: analysis of the features in 170 patients. Respir Med. 2003;97(8):978–82.PubMedCrossRef
11.
Hattori T, Konno S, Shijubo N, Yamaguchi T, Sugiyama Y, Honma S, et al. Nationwide survey on the organ-specific prevalence and its interaction with sarcoidosis in Japan. Sci Rep. 2018;8(1):9440.PubMedPubMedCentralCrossRef
12.
Dumas O, Abramovitz L, Wiley AS, Cozier YC, Camargo CA Jr. Epidemiology of sarcoidosis in a prospective cohort study of US women. Ann Am Thorac Soc. 2016;13(1):67–71.PubMedPubMedCentralCrossRef
13.
Sawahata M, Sugiyama Y, Nakamura Y, Nakayama M, Mato N, Yamasawa H, et al. Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan. Respir Med. 2015;109(2):272–8.PubMedCrossRef
14.
Jamilloux Y, Bonnefoy M, Valeyre D, Varron L, Broussolle C, Seve P. Elderly-onset sarcoidosis: prevalence, clinical course, and treatment. Drugs Aging. 2013;30(12):969–78.PubMedCrossRef
15.
Ungprasert P, Crowson CS, Matteson EL. Seasonal variation in incidence of sarcoidosis: a population-based study, 1976–2013. Thorax. 2016;71(12):1164–6.PubMedCrossRef
16.
Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016;48(6):1690–9.PubMedCrossRef
17.
Sikjaer MG, Hilberg O, Ibsen R, Lokke A. Sarcoidosis: a nationwide registry-based study of incidence, prevalence and diagnostic work-up. Respir Med. 2021;30(187): 106548.CrossRef
18.
Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc. 2016;13(8):1244–52.PubMedCrossRef
19.
Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007;28(1):22–35.PubMedCrossRef
20.
Rybicki BA, Maliarik MJ, Major M, Popovich J Jr, Iannuzzi MC. Epidemiology, demographics, and genetics of sarcoidosis. Semin Respir Infect. 1998;13(3):166–73.PubMed
21.
Birnbaum AD, Rifkin LM. Sarcoidosis: sex-dependent variations in presentation and management. J Ophthalmol. 2014;2014: 236905.PubMedPubMedCentral
22.
Byg KE, Milman N, Hansen S. Sarcoidosis in Denmark 1980–1994. A registry-based incidence study comprising 5536 patients. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(1):46–52.PubMed
23.
Milman N, Selroos O. Pulmonary sarcoidosis in the Nordic countries 1950–1982. Epidemiology and clinical picture. Sarcoidosis. 1990;7(1):50–7.PubMed
24.
Morimoto T, Azuma A, Abe S, Usuki J, Kudoh S, Sugisaki K, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31(2):372–9.PubMedCrossRef
25.
26.
Cozier YC, Berman JS, Palmer JR, Boggs DA, Serlin DM, Rosenberg L. Sarcoidosis in black women in the United States: data from the Black Women’s Health Study. Chest. 2011;139(1):144–50.PubMedCrossRef
27.
Tukey MH, Berman JS, Boggs DA, White LF, Rosenberg L, Cozier YC. Mortality among African American women with sarcoidosis: data from the Black Women’s Health Study. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(2):128–33.PubMed
28.
Kassamali B, Villa-Ruiz C, Kus KJB, Mazori DR, Kassamali AA, Gizelis O, Vleugels RA, LaChance AH, Imadojemu S. Increased risk of systemic and cardiac sarcoidosis in Black patients with cutaneous sarcoidosis. J Am Acad Dermatol. 2022;86(5):1178–80.PubMedCrossRef
29.
Evans M, Sharma O, LaBree L, Smith RE, Rao NA. Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis. Ophthalmology. 2007;114(2):325–33.PubMedCrossRef
30.
Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147(2):438–49.PubMedCrossRef
31.
Iwai K, Sekiguti M, Hosoda Y, DeRemee RA, Tazelaar HD, Sharma OP, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11(1):26–31.PubMed
32.
Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979–1991: an analysis of multiple-cause mortality data. Am J Med. 1996;100(4):423–7.PubMedCrossRef
33.
Varron L, Cottin V, Schott AM, Broussolle C, Seve P. Late-onset sarcoidosis: a comparative study. Medicine (Baltimore). 2012;91(3):137–43.CrossRef
34.
Ungprasert P, Wetter DA, Crowson CS, Matteson EL. Epidemiology of cutaneous sarcoidosis, 1976–2013: a population-based study from Olmsted County, Minnesota. J Eur Acad Dermatol Venereol. 2016;30(10):1799–804.PubMedPubMedCentralCrossRef
35.
Sverrild A, Backer V, Kyvik KO, Kaprio J, Milman N, Svendsen CB, et al. Heredity in sarcoidosis: a registry-based twin study. Thorax. 2008;63(10):894–6.PubMedCrossRef
36.
Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, et al. Familial aggregation of sarcoidosis. A case–control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164(11):2085–91.PubMedCrossRef
37.
Rybicki BA, Kirkey KL, Major M, Maliarik MJ, Popovich J Jr, Chase GA, et al. Familial risk ratio of sarcoidosis in African–American sibs and parents. Am J Epidemiol. 2001;153(2):188–93.PubMedCrossRef
38.
Rossides M, Grunewald J, Eklund A, Kullberg S, Di Giuseppe D, Askling J, Arkema EV. Familial aggregation and heritability of sarcoidosis: a Swedish nested case-control study. Eur Respir J. 2018;52(2):1800385.PubMedCrossRef
39.
Cleven KL, Ye K, Zeig-Owens R, Hena KM, Montagna C, Shan J, et al. Genetic variants associated with FDNY WTC-related sarcoidosis. Int J Environ Res Public Health. 2019;16(10):1830.PubMedCentralCrossRef
40.
Levin AM, Adrianto I, Datta I, Iannuzzi MC, Trudeau S, Li J, et al. Association of HLA-DRB1 with sarcoidosis susceptibility and progression in African Americans. Am J Respir Cell Mol Biol. 2015;53(2):206–16.PubMedPubMedCentralCrossRef
41.
Rivera NV, Patasova K, Kullberg S, Diaz-Gallo LM, Iseda T, Bengtsson C, et al. A gene–environment interaction between smoking and gene polymorphisms provides a high risk of two subgroups of sarcoidosis. Sci Rep. 2019;9(1):18633.PubMedPubMedCentralCrossRef
42.
Zhou H, Diao M, Zhang M. The association between ANXA11 gene polymorphisms and sarcoidosis: a meta-analysis and systematic review. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(2):102–11.PubMed
43.
Wolin A, Lahtela EL, Anttila V, Petrek M, Grunewald J, van Moorsel CHM, et al. SNP variants in major histocompatibility complex are associated with sarcoidosis susceptibility—a joint analysis in four European populations. Front Immunol. 2017;8:422.PubMedPubMedCentralCrossRef
44.
Bello GA, Adrianto I, Dumancas GG, Levin AM, Iannuzzi MC, Rybicki BA, et al. Role of NOD2 pathway genes in sarcoidosis cases with clinical characteristics of Blau syndrome. Am J Respir Crit Care Med. 2015;192(9):1133–5.PubMedPubMedCentralCrossRef
45.
Schnerch J, Prasse A, Vlachakis D, Schuchardt KL, Pechkovsky DV, Goldmann T, et al. Functional toll-like receptor 9 expression and CXCR3 ligand release in pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 2016;55(5):749–57.PubMedCrossRef
46.
Calender A, Weichhart T, Valeyre D, Pacheco Y. Current insights in genetics of sarcoidosis: functional and clinical impacts. J Clin Med. 2020;9(8):2633.PubMedCentralCrossRef
47.
Fritz D, Ferwerda B, Brouwer MC, van de Beek D. Whole genome sequencing identifies variants associated with sarcoidosis in a family with a high prevalence of sarcoidosis. Clin Rheumatol. 2021;40(9):3735–43.PubMedPubMedCentralCrossRef
48.
Lahtela E, Kankainen M, Sinisalo J, Selroos O, Lokki ML. Exome sequencing identifies susceptibility loci for sarcoidosis prognosis. Front Immunol. 2019;10:2964.PubMedPubMedCentralCrossRef
49.
Kishore A, Petersen BS, Nutsua M, Muller-Quernheim J, Franke A, Fischer A, et al. Whole-exome sequencing identifies rare genetic variations in German families with pulmonary sarcoidosis. Hum Genet. 2018;137(9):705–16.PubMedCrossRef
50.
Calender A, Lim CX, Weichhart T, Buisson A, Besnard V, Rollat-Farnier PA, Bardel C, Roy P, Cottin V, Devouassoux G, Finat A, Pinson S, Lebecque S, Nunes H, Israel-Biet D, Bentaher A, Valeyre D, Pacheco Y; in the frame of GSF (Group Sarcoidosis France). Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis. Eur Respir J. 2019;54(2):1900430.PubMedCrossRef
51.
Suwinski P, Ong C, Ling MHT, Poh YM, Khan AM, Ong HS. Advancing personalized medicine through the application of whole exome sequencing and big data analytics. Front Genet. 2019;10:49.PubMedPubMedCentralCrossRef
52.
Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–84.PubMedCrossRef
53.
Floss DM, Moll JM, Scheller J. IL-12 and IL-23-close relatives with structural homologies but distinct immunological functions. Cells. 2020;9(10):2184.PubMedCentralCrossRef
54.
55.
Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol. 2017;24(1):59–65.PubMedCrossRef
56.
Wang A, Singh K, Ibrahim W, King B, Damsky W. The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature. Yale J Biol Med. 2020;93(1):187–95.PubMedPubMedCentral
57.
Zhou T, Casanova N, Pouladi N, Wang T, Lussier Y, Knox KS, et al. Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature. Sci Rep. 2017;7(1):4237.PubMedPubMedCentralCrossRef
58.
Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of multiorgan sarcoidosis with tofacitinib. ACR Open Rheumatol. 2020;2(2):106–9.PubMedPubMedCentralCrossRef
59.
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82(3):612–21.PubMedCrossRef
60.
Moller DR, Rybicki BA, Hamzeh NY, Montgomery CG, Chen ES, Drake W, et al. Genetic, immunologic, and environmental basis of sarcoidosis. Ann Am Thorac Soc. 2017;14(Supplement_6):S429–36.PubMedPubMedCentralCrossRef
61.
Esteves T, Aparicio G, Garcia-Patos V. Is there any association between sarcoidosis and infectious agents?: A systematic review and meta-analysis. BMC Pulm Med. 2016;16(1):165.PubMedPubMedCentralCrossRef
62.
Zhou Y, Hu Y, Li H. Role of propionibacterium acnes in sarcoidosis: a meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(4):262–7.PubMed
63.
Knoell KA, Hendrix JD Jr, Stoler MH, Patterson JW, Montes CM. Absence of human herpesvirus 8 in sarcoidosis and crohn disease granulomas. Arch Dermatol. 2005;141(7):909–10.PubMedCrossRef
64.
Derler AM, Eisendle K, Baltaci M, Obermoser G, Zelger B. High prevalence of “Borrelia-like” organisms in skin biopsies of sarcoidosis patients from Western Austria. J Cutan Pathol. 2009;36(12):1262–8.PubMedCrossRef
65.
Shields BE, Perelygina L, Samimi S, Haun P, Leung T, Abernathy E, et al. Granulomatous dermatitis associated with rubella virus infection in an adult with immunodeficiency. JAMA Dermatol. 2021;157(7):842–7.PubMedCrossRef
66.
Chen ES, Moller DR. Sarcoidosis—scientific progress and clinical challenges. Nat Rev Rheumatol. 2011;7(8):457–67.PubMedCrossRef
67.
Drake WP, Culver DA, Baughman RP, Judson MA, Crouser ED, James WE, et al. Phase II investigation of the efficacy of antimycobacterial therapy in chronic pulmonary sarcoidosis. Chest. 2021;159(5):1902–12.PubMedCrossRef
68.
Chen ES, Wahlstrom J, Song Z, Willett MH, Wiken M, Yung RC, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol. 2008;181(12):8784–96.PubMedCrossRef
69.
Song Z, Marzilli L, Greenlee BM, Chen ES, Silver RF, Askin FB, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005;201(5):755–67.PubMedPubMedCentralCrossRef
70.
Bindoli S, Dagan A, Torres-Ruiz JJ, Perricone C, Bizjak M, Doria A, et al. Sarcoidosis and autoimmunity: from genetic background to environmental factors. Isr Med Assoc J. 2016;18(3–4):197–202.PubMed
71.
72.
Armbruster C, Dekan G, Hovorka A. Granulomatous pneumonitis and mediastinal lymphadenopathy due to photocopier toner dust. Lancet. 1996;348(9028):690.PubMedCrossRef
73.
74.
Kim YC, Triffet MK, Gibson LE. Foreign bodies in sarcoidosis. Am J Dermatopathol. 2000;22(5):408–12.PubMedCrossRef
75.
Ball NJ, Kho GT, Martinka M. The histologic spectrum of cutaneous sarcoidosis: a study of twenty-eight cases. J Cutan Pathol. 2004;31(2):160–8.PubMedCrossRef
76.
Mayer AS, Hamzeh N, Maier LA. Sarcoidosis and chronic beryllium disease: similarities and differences. Semin Respir Crit Care Med. 2014;35(3):316–29.PubMedCrossRef
77.
Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170(12):1324–30.PubMedCrossRef
78.
Izbicki G, Chavko R, Banauch GI, Weiden MD, Berger KI, Aldrich TK, et al. World Trade Center “sarcoid-like” granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest. 2007;131(5):1414–23.PubMedCrossRef
79.
Hena KM, Yip J, Jaber N, Goldfarb D, Fullam K, Cleven K, et al. Clinical course of sarcoidosis in world trade center-exposed firefighters. Chest. 2018;153(1):114–23.PubMedCrossRef
80.
Papanikolaou IC, Tabila B, Tabila K, Borok Z, Sharma O, Gould MK. Vitamin D status in sarcoidosis: a cross-sectional study. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(2):154–9.PubMedPubMedCentral
81.
Kiani A, Abedini A, Adcock IM, Mirenayat MS, Taghavi K, Mortaz E, et al. Association between vitamin D deficiencies in sarcoidosis with disease activity, course of disease and stages of lung involvements. J Med Biochem. 2018;37(2):103–9.PubMedPubMedCentralCrossRef
82.
83.
Hamada K, Nagai S, Tsutsumi T, Izumi T. Ionized calcium and 1,25-dihydroxyvitamin D concentration in serum of patients with sarcoidosis. Eur Respir J. 1998;11(5):1015–20.PubMedCrossRef
84.
Adams JS, Diz MM, Sharma OP. Effective reduction in the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia with short-course chloroquine therapy. Ann Intern Med. 1989;111(5):437–8.PubMedCrossRef
85.
Wu CH, Chung PI, Wu CY, Chen YT, Chiu YW, Chang YT, et al. Comorbid autoimmune diseases in patients with sarcoidosis: a nationwide case-control study in Taiwan. J Dermatol. 2017;44(4):423–30.PubMedCrossRef
86.
Migita K, Udono M, Kinoshita A, Osumi M, Ito M, Miyashita T, et al. Lupus erythematosus and sarcoidosis. Clin Rheumatol. 2005;24(3):312–3.PubMedCrossRef
87.
Santiago T, Santiago M, Rovisco J, Ferreira J, Duarte C, Malcata A, et al. Coexisting primary Sjogren’s syndrome and sarcoidosis: coincidence, mutually exclusive conditions or syndrome? Rheumatol Int. 2014;34(11):1619–22.PubMedCrossRef
88.
Antonelli A, Fazzi P, Fallahi P, Ferrari SM, Ferrannini E. Prevalence of hypothyroidism and Graves disease in sarcoidosis. Chest. 2006;130(2):526–32.PubMedCrossRef
89.
Starshinova AA, Malkova AM, Basantsova NY, Zinchenko YS, Kudryavtsev IV, Ershov GA, et al. Sarcoidosis as an autoimmune disease. Front Immunol. 2019;10:2933.PubMedCrossRef
90.
Musaelyan A, Lapin S, Nazarov V, Tkachenko O, Gilburd B, Mazing A, et al. Vimentin as antigenic target in autoimmunity: a comprehensive review. Autoimmun Rev. 2018;17(9):926–34.PubMedCrossRef
91.
Kinloch AJ, Kaiser Y, Wolfgeher D, Ai J, Eklund A, Clark MR, et al. In situ humoral immunity to vimentin in HLA-DRB1*03(+) patients with pulmonary sarcoidosis. Front Immunol. 2018;9:1516.PubMedPubMedCentralCrossRef
92.
Song M, Manansala M, Parmar PJ, Ascoli C, Rubinstein I, Sweiss NJ. Sarcoidosis and autoimmunity. Curr Opin Pulm Med. 2021;27(5):448–54.PubMedCrossRef
93.
Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol. 2012;66(5):699 e1-18 (quiz 717–8).CrossRef
94.
Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Lancet Respir Med. 2018;6(5):389–402.PubMedCrossRef
95.
Steffen M, Petersen J, Oldigs M, Karmeier A, Magnussen H, Thiele HG, et al. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol. 1993;91(4):939–49.PubMedCrossRef
96.
Celada LJ, Drake WP. Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy? Immunotherapy. 2015;7(1):57–66.PubMedCrossRef
97.
Ostadkarampour M, Eklund A, Moller D, Glader P, Olgart Hoglund C, Linden A, et al. Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Lofgren’s syndrome. Clin Exp Immunol. 2014;178(2):342–52.PubMedPubMedCentralCrossRef
98.
Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K. The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp (Warsz). 2015;63(6):435–49.CrossRef
99.
100.
Ten Berge B, Paats MS, Bergen IM, van den Blink B, Hoogsteden HC, Lambrecht BN, et al. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxford). 2012;51(1):37–46.CrossRef
101.
Facco M, Cabrelle A, Teramo A, Olivieri V, Gnoato M, Teolato S, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax. 2011;66(2):144–50.PubMedCrossRef
102.
Wu W, Jin M, Wang Y, Liu B, Shen D, Chen P, et al. Overexpression of IL-17RC associated with ocular sarcoidosis. J Transl Med. 2014;31(12):152.CrossRef
103.
Song J, Zhao M, Li Q, Lu L, Zhou Y, Zhang Y, et al. IL-17A Can Promote propionibacterium acnes-induced sarcoidosis-like granulomatosis in mice. Front Immunol. 2019;10:1923.PubMedPubMedCentralCrossRef
104.
Ramstein J, Broos CE, Simpson LJ, Ansel KM, Sun SA, Ho ME, et al. IFN-gamma-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med. 2016;193(11):1281–91.PubMedPubMedCentralCrossRef
105.
Zhou ER, Arce S. Key players and biomarkers of the adaptive immune system in the pathogenesis of sarcoidosis. Int J Mol Sci. 2020;21(19):7398.PubMedCentralCrossRef
106.
Bauer L, Müller LJ, Volkers SM, Heinrich F, Mashreghi MF, Ruppert C, Sander LE, Hutloff A. Follicular Helper-like T Cells in the Lung Highlight a Novel Role of B Cells in Sarcoidosis. Am J Respir Crit Care Med. 2021;204(12):1403–17.PubMedPubMedCentralCrossRef
107.
108.
Ando M, Goto A, Takeno Y, Yamasue M, Komiya K, Umeki K, et al. Significant elevation of the levels of B-cell activating factor (BAFF) in patients with sarcoidosis. Clin Rheumatol. 2018;37(10):2833–8.PubMedCrossRef
109.
Lee NS, Barber L, Akula SM, Sigounas G, Kataria YP, Arce S. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol. 2011;18(8):1306–16.PubMedPubMedCentralCrossRef
110.
111.
Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell. 2010;40(2):310–22.PubMedPubMedCentralCrossRef
112.
Jung J, Zeng H, Horng T. Metabolism as a guiding force for immunity. Nat Cell Biol. 2019;21(1):85–93.PubMedCrossRef
113.
114.
Pacheco Y, Lim CX, Weichhart T, Valeyre D, Bentaher A, Calender A. Sarcoidosis and the mTOR, Rac1, and autophagy triad. Trends Immunol. 2020;41(4):286–99.PubMedCrossRef
115.
Linke M, Pham HT, Katholnig K, Schnoller T, Miller A, Demel F, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol. 2017;18(3):293–302.PubMedPubMedCentralCrossRef
116.
Pizzini A, Bacher H, Aichner M, Franchi A, Watzinger K, Tancevski I, et al. High expression of mTOR signaling in granulomatous lesions is not predictive for the clinical course of sarcoidosis. Respir Med. 2021;5(177): 106294.CrossRef
117.
Kim YM, Park JM, Grunwald D, Kim DH. An expanded role for mTORC1 in autophagy. Mol Cell Oncol. 2016;3(1): e1010958.PubMedCrossRef
118.
Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19(6):349–64.PubMedCrossRef
119.
Crouser ED, Locke LW, Julian MW, Bicer S, Sadee W, White P, Schlesinger LS. Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis. Eur Respir J. 2021;57(3):2002695.PubMedCrossRef
120.
121.
Abedini A, Naderi Z, Kiani A, Marjani M, Mortaz E, Ghorbani F. The evaluation of interleukin-4 and interleukin-13 in the serum of pulmonary sarcoidosis and tuberculosis patients. J Res Med Sci. 2020;25:24.PubMedPubMedCentral
122.
Locke LW, Crouser ED, White P, Julian MW, Caceres EG, Papp AC, et al. IL-13-regulated macrophage polarization during granuloma formation in an in vitro human sarcoidosis model. Am J Respir Cell Mol Biol. 2019;60(1):84–95.PubMedPubMedCentralCrossRef
123.
124.
Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–73.PubMed
125.
Garcia-Colmenero L, Sanchez-Schmidt JM, Barranco C, Pujol RM. The natural history of cutaneous sarcoidosis. Clinical spectrum and histological analysis of 40 cases. Int J Dermatol. 2019;58(2):178–84.PubMedCrossRef
126.
Mana J, Marcoval J, Graells J, Salazar A, Peyri J, Pujol R. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol. 1997;133(7):882–8.PubMedCrossRef
127.
Villa-Ruiz C, Lo K, Desai S, Vleugels RA, Imadojemu S. Practice gaps in the evaluation of systemic involvement in patients with cutaneous sarcoidosis presenting to a dermatologist: a retrospective review of 48 patients. J Am Acad Dermatol. 2021;85(3):794–6.PubMedCrossRef
128.
Ribeiro Neto ML, Jellis CL, Joyce E, Callahan TD, Hachamovitch R, Culver DA. Update in cardiac sarcoidosis. Ann Am Thorac Soc. 2019;16(11):1341–50.PubMedCrossRef
129.
Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther. 2016;6(1):50–63.PubMedPubMedCentral
130.
Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al. Diagnosis and detection of sarcoidosis. An Official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(8):e26–51.PubMedPubMedCentralCrossRef
131.
Ungprasert P, Ryu JH, Matteson EL. Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clin Proc Innov Qual Outcomes. 2019;3(3):358–75.PubMedPubMedCentralCrossRef
132.
Yeung H, Farber S, Birnbaum BK, Dunham J, Ogdie A, Patterson KC, et al. Reliability and validity of cutaneous sarcoidosis outcome instruments among dermatologists, pulmonologists, and rheumatologists. JAMA Dermatol. 2015;151(12):1317–22.PubMedCrossRef
133.
Baughman RP, Judson MA, Ingledue R, Craft NL, Lower EE. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol. 2012;148(2):262–4.PubMedCrossRef
134.
Baughman RP, Judson MA, Teirstein A, Lower EE, Lo K, Schlenker-Herceg R, et al. Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol. 2008;9(3):155–61.PubMedCrossRef
135.
Drake WP, Oswald-Richter K, Richmond BW, Isom J, Burke VE, Algood H, et al. Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study. JAMA Dermatol. 2013;149(9):1040–9.PubMedPubMedCentralCrossRef
136.
Rosenbach M, Yeung H, Chu EY, Kim EJ, Payne AS, Takeshita J, et al. Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol. 2013;149(5):550–6.PubMedCrossRef
137.
Noe MH, Gelfand JM, Bryer JS, Price SN, Judson MA, Rosenbach M. Responsiveness to change and establishment of the minimal clinically important difference for the cutaneous sarcoidosis activity and morphology instrument. JAMA Dermatol. 2020;156(1):98–9.PubMedCrossRef
138.
Caplan A, Rosenbach M, Imadojemu S. Cutaneous sarcoidosis. Semin Respir Crit Care Med. 2020;41(5):689–99.PubMedCrossRef
139.
Hasegawa T, Suga Y, Mizuno Y, Haruna K, Ikeda S. Photodynamic therapy using intense pulsed light for cutaneous sarcoidosis. J Dermatol. 2012;39(6):564–5.PubMedCrossRef
140.
Green CM. Topical tacrolimus for the treatment of cutaneous sarcoidosis. Clin Exp Dermatol. 2007;32(4):457–8.PubMedCrossRef
141.
Singh SK, Singh S, Pandey SS. Cutaneous sarcoidosis without systemic involvement: response to intralesional corticosteroid. Indian J Dermatol Venereol Leprol. 1996;62(4):273–4.PubMedCrossRef
142.
Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990;23(3 Pt 1):487–9.PubMedCrossRef
143.
Park MK, Fontana, Jr, Babaali H, Gilbert-McClain LI, Stylianou M, Joo J, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26(2):121-31.
144.
Imadojemu SWK, Noe M, English JC, Rosenbach M. Cutaneous sarcoidosis. In: Baughman RPVD, editor. Sarcoidosis, a clinician’s guide. Amsterdam: Elsevier; 2019. p. 127–44.
145.
Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008;68(10):1361–83.PubMedCrossRef
146.
Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, Rottoli P, Nunes H, Lower EE, Judson MA, Israel-Biet D, Grutters JC, Drent M, Culver DA, Bonella F, Antoniou K, Martone F, Quadder B, Spitzer G, Nagavci B, Tonia T, Rigau D, Ouellette DR. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6):2004079.PubMedCrossRef
147.
Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: gastrointestinal and endocrinologic side effects. J Am Acad Dermatol. 2017;76(1):11–6.PubMedCrossRef
148.
Paolino A, Galloway J, Birring S, Brex P, Larkin G, Patel A, et al. Clinical phenotypes and therapeutic responses in cutaneous-predominant sarcoidosis: 6-year experience in a tertiary referral service. Clin Exp Dermatol. 2021;46(6):1038–45.PubMedCrossRef
149.
Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013;68(5):765–73.PubMedCrossRef
150.
Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol. 2005;141(7):910–1.PubMedCrossRef
151.
Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009;135(2):468–76.PubMedCrossRef
152.
Field S, Regan AO, Sheahan K, Collins P. Recalcitrant cutaneous sarcoidosis responding to adalimumab but not to etanercept. Clin Exp Dermatol. 2010;35(7):795–6.PubMedCrossRef
153.
Thielen AM, Barde C, Saurat JH, Laffitte E. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists. Dermatology. 2009;219(1):59–62.PubMedCrossRef
154.
Heidelberger V, Ingen-Housz-Oro S, Marquet A, Mahevas M, Bessis D, Bouillet L, et al. Efficacy and tolerance of anti-tumor necrosis factor alpha agents in cutaneous sarcoidosis: a French study of 46 cases. JAMA Dermatol. 2017;153(7):681–5.PubMedPubMedCentralCrossRef
155.
Daien CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–6.CrossRef
156.
Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis. 2012;6(6):708–12.PubMedCrossRef
157.
Jamilloux Y, El Jammal T, Vuitton L, Gerfaud-Valentin M, Kerever S, Seve P. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019;18(11): 102390.PubMedCrossRef
158.
Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford). 2019;58(Suppl 1):i43–54.CrossRef
159.
Wei JJ, Kallenbach LR, Kreider M, Leung TH, Rosenbach M. Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera. JAAD Case Rep. 2019;5(4):360–1.PubMedPubMedCentralCrossRef
160.
Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540–6.PubMedPubMedCentralCrossRef
161.
Rotenberg C, Besnard V, Brillet PY, Giraudier S, Nunes H, Valeyre D. Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia. Eur Respir J. 2018 Dec 20;52(6):1801482.
162.
Rosenbach M. Janus kinase inhibitors offer promise for a new era of targeted treatment for granulomatous disorders. J Am Acad Dermatol. 2020;82(3):e91–2.PubMedCrossRef
163.
Scheinberg M, Maluf F, Wagner J. Steroid-resistant sarcoidosis treated with baricitinib. Ann Rheum Dis. 2020;79(9):1259–60.PubMedCrossRef
164.
Levraut M, Martis N, Viau P, Suarez F, Queyrel V. Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib. Ann Rheum Dis. 2019;78(11):1606–7.PubMedCrossRef
165.
Judson MA. Corticosteroid-sparing drugs in sarcoidosis: how should we assess them? Lung. 2021;199(2):85–6.PubMedCrossRef
166.
Friedman MA, Le B, Stevens J, Desmarais J, Seifer D, Ogle K, et al. Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study. Lung. 2021;199(2):147–53.PubMedPubMedCentralCrossRef
167.
Alam M, Fang V, Rosenbach M. Treatment of cutaneous sarcoidosis with tofacitinib 2% ointment and extra virgin olive oil. JAAD Case Rep. 2021;9:1–3.PubMedCrossRef
168.
Singh K, Wang A, Heald P, McNiff JM, Suozzi K, King B, et al. Treatment of angiolupoid sarcoidosis with tofacitinib ointment 2% and pulsed dye laser therapy. JAAD Case Rep. 2021;7:122–4.PubMedCrossRef
169.
Wu KK, Dao H Jr. Off-label dermatologic uses of IL-17 inhibitors. J Dermatol Treat. 2020;9:1–7.
170.
Sambharia MMT, Ramakrishna S. Worsening of pulmonary sarcoidosis induced by ixekizumab: a rare paradox. Chest. 2018;154:898A.CrossRef
171.
Eichhoff G. Management with secukinumab of tumour necrosis factor inhibitor-induced pulmonary sarcoidosis-like reaction in a patient with psoriasis. Clin Exp Dermatol. 2020;45(4):455–6.PubMedCrossRef
172.
Toussirot E, Bernard C, Bossert M. Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis. Clin Exp Rheumatol. 2019;37(2):344–5.PubMed
173.
Nyckowski TCR, Wilson J. Sarcoidosis developing during secukinumab therapy: case report. SKIN J Cutan Med. 2017;1:95–9.CrossRef
174.
175.
Powell MD, Read KA, Sreekumar BK, Jones DM, Oestreich KJ. IL-12 signaling drives the differentiation and function of a TH1-derived TFH1-like cell population. Sci Rep. 2019;9(1):13991.PubMedPubMedCentralCrossRef
176.
Mroz RM, Korniluk M, Stasiak-Barmuta A, Chyczewska E. Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. J Physiol Pharmacol. 2008;59(Suppl 6):507–13.PubMed
177.
Shigehara K, Shijubo N, Ohmichi M, Kamiguchi K, Takahashi R, Morita-Ichimura S, et al. Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clin Exp Immunol. 2003;132(1):152–7.PubMedPubMedCentralCrossRef
178.
Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–45.PubMedPubMedCentralCrossRef
179.
Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014;44(5):1296–307.PubMedCrossRef
180.
Thomas AS, Rosenbaum JT. Poor control of sarcoidosis-related panuveitis with an antibody to IL-23. Ocul Immunol Inflamm. 2020;28(3):491–3.PubMedCrossRef
181.
Gad MM, Bazarbashi N, Kaur M, Gupta A. Sarcoid-like phenomenon—ustekinumab induced granulomatous reaction mimicking diffuse metastatic disease: a case report and review of the literature. J Med Case Rep. 2019;13(1):257.PubMedPubMedCentralCrossRef
182.
Powell JB, Matthews P, Rattehalli R, Woodhead F, Perkins P, Powell G, et al. Acute systemic sarcoidosis complicating ustekinumab therapy for chronic plaque psoriasis. Br J Dermatol. 2015;172(3):834–6.PubMedCrossRef
183.
Kobak S, Semiz H. Ustekinumab-induced sarcoidosis in a patient with psoriatic arthritis. Curr Drug Saf. 2020;15(2):163–6.PubMedCrossRef
184.
Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. J Clin Invest. 1981;67(1):86–92.PubMedPubMedCentralCrossRef
185.
Cinetto F, Compagno N, Scarpa R, Malipiero G, Agostini C. Rituximab in refractory sarcoidosis: a single centre experience. Clin Mol Allergy. 2015;13(1):19.PubMedPubMedCentralCrossRef
186.
Zella S, Kneiphof J, Haghikia A, Gold R, Woitalla D, Thone J. Successful therapy with rituximab in three patients with probable neurosarcoidosis. Ther Adv Neurol Disord. 2018;11:1756286418805732.PubMedPubMedCentralCrossRef
187.
Bomprezzi R, Pati S, Chansakul C, Vollmer T. A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010;75(6):568–70.PubMedCrossRef
188.
Krause ML, Cooper LT, Chareonthaitawee P, Amin S. Successful use of rituximab in refractory cardiac sarcoidosis. Rheumatology (Oxford). 2016;55(1):189–91.CrossRef
189.
Elwazir M, Krause ML, Bois JP, Christopoulos G, Kendi AT, Cooper JLT, Jouni H, Abouezzeddine OF, Chareonthaitawee P, Abdelshafee M, Amin S. Rituximab for the Treatment of Refractory Cardiac Sarcoidosis: A Single-Center Experience. J Card Fail. 2022;28(2):247–58.PubMedCrossRef
190.
Sweiss NJ, Lower EE, Mirsaeidi M, Dudek S, Garcia JG, Perkins D, et al. Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J. 2014;43(5):1525–8.PubMedPubMedCentralCrossRef
191.
Vesely NC, Thomas RM, Rudnick E, Longo MI. Scar sarcoidosis following rituximab therapy. Dermatol Ther. 2020;33(6): e13693.PubMedCrossRef
192.
Pescitelli L, Emmi G, Tripo L, Lazzeri L, Urban ML, Silvesri E, et al. Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: an uncommon adverse effect? Eur J Dermatol. 2017;27(6):667–8.PubMedCrossRef
193.
Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001;137(1):69–73.PubMedCrossRef
194.
Marshall TG, Marshall FE. Sarcoidosis succumbs to antibiotics—implications for autoimmune disease. Autoimmun Rev. 2004;3(4):295–300.PubMedCrossRef
195.
Beijer E, Seldenrijk K, Eishi Y, Uchida K, Damen J, Grutters JC, Veltkamp M. Presence of Propionibacterium acnes in granulomas associates with a chronic disease course in Dutch sarcoidosis patients. ERJ Open Res. 2021;7(1):00486-2020.PubMedPubMedCentralCrossRef
196.
Ishibashi K, Eishi Y, Tahara N, Asakura M, Sakamoto N, Nakamura K, et al. Japanese Antibacterial Drug Management for Cardiac Sarcoidosis (J-ACNES): a multicenter, open-label, randomized, controlled study. J Arrhythm. 2018;34(5):520–6.PubMedPubMedCentralCrossRef
197.
Drake WP, Richmond BW, Oswald-Richter K, Yu C, Isom JM, Worrell JA, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(3):201–11.PubMed
198.
Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–57.PubMedCrossRef
199.
Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–45.PubMedPubMedCentralCrossRef
200.
Soric Hosman I, Kos I, Lamot L. Serum amyloid A in inflammatory rheumatic diseases: a compendious review of a renowned biomarker. Front Immunol. 2020;11: 631299.PubMedCrossRef
201.
202.
Chen ES, Song Z, Willett MH, Heine S, Yung RC, Liu MC, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010;181(4):360–73.PubMedCrossRef
203.
Schanz S, Schmalzing M, Guenova E, Metzler G, Ulmer A, Kotter I, et al. Interstitial granulomatous dermatitis with arthritis responding to tocilizumab. Arch Dermatol. 2012;148(1):17–20.PubMedCrossRef
204.
Sharp M, Donnelly SC, Moller DR. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med X. 2019;1:100004.PubMedPubMedCentral
205.
Theodosiou G, Luu H, Svensson A. Tocilizumab-induced sarcoidosis-like reaction in a patient with giant cell arteritis. Clinical implications of a paradoxical phenomenon. Int J Dermatol. 2020;59(7):888–9.PubMedCrossRef
206.
Lambert N, Hansen I, El Moussaoui M, Giot JB, Vercheval C, Lommers É, Somja J, Moutschen M, Maquet P. Lung and liver sarcoidosis-like reaction induced by tocilizumab. Br J Clin Pharmacol. 2021;87(12):4848–52.PubMedCrossRef
207.
Nutz A, Pernet C, Combe B, Cohen JD. Sarcoidosis induced by tocilizumab: a paradoxical event? J Rheumatol. 2013;40(10):1773–4.PubMedCrossRef
208.
Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–55.PubMedCrossRef
209.
Obi ON, Lower EE, Baughman RP. Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Expert Rev Clin Pharmacol. 2021;14(2):179–210.PubMedCrossRef
210.
Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508–11.PubMedCrossRef
211.
Tong Z, Dai H, Chen B, Abdoh Z, Guzman J, Costabel U. Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline: comparison with dexamethasone. Chest. 2003;124(4):1526–32.PubMedCrossRef
212.
Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med. 1997;155(5):1665–9.PubMedCrossRef
213.
Imadojemu S, Wanat KA, Noe M, English JC, Rosenbach M. Cutaneous sarcoidosis. In: RP B, editor. Sarcoidosis, a clinician’s guide. Amsterdam: Elsevier; 2019. p. 127–44.
214.
Baughman RP, Judson MA, Culver DA, Birring SS, Parambil J, Zeigler J, et al. Roflumilast (Daliresp(R)) to reduce acute pulmonary events in fibrotic sarcoidosis: a multi-center, double blind, placebo controlled, randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis. 2021;38(3): e2021035.PubMedPubMedCentral
215.
Manzia TM, Bellini MI, Corona L, Toti L, Fratoni S, Cillis A, et al. Successful treatment of systemic de novo sarcoidosis with cyclosporine discontinuation and provision of rapamune after liver transplantation. Transpl Int. 2011;24(8):e69-70.PubMedCrossRef
216.
Gupta N, Bleesing JH, McCormack FX. Successful response to treatment with sirolimus in pulmonary sarcoidosis. Am J Respir Crit Care Med. 2020;202(9):e119–20.PubMedCrossRef
217.
Kelleher KJ, Russell J, Killeen OG, Leahy TR. Treatment-recalcitrant laryngeal sarcoidosis responsive to sirolimus. BMJ Case Rep. 2020;13(8):e235372.PubMedCrossRef
218.
Yanardag H, Tetikkurt C, Bilir M, Yilmaz E. Association of HLA antigens with the clinical course of sarcoidosis and familial disease. Monaldi Arch Chest Dis. 2017;87(3):835.PubMedCrossRef
219.
Grunewald J, Eklund A. Lofgren’s syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med. 2009;179(4):307–12.PubMedCrossRef
220.
Morais A, Lima B, Alves H, Melo N, Mota PC, Marques A, et al. Associations between sarcoidosis clinical course and ANXA11 rs1049550 C/T, BTNL2 rs2076530 G/A, and HLA class I and II alleles. Clin Respir J. 2018;12(2):532–7.PubMedCrossRef
221.
Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73(4):720–35.PubMedPubMedCentralCrossRef
222.
Garman L, Pezant N, Pastori A, Savoy KA, Li C, Levin AM, et al. Genome-wide association study of ocular sarcoidosis confirms HLA associations and implicates barrier function and autoimmunity in African Americans. Ocul Immunol Inflamm. 2021;29(2):244–9.PubMedCrossRef
223.
Naruse TK, Matsuzawa Y, Ota M, Katsuyama Y, Matsumori A, Hara M, et al. HLA-DQB1*0601 is primarily associated with the susceptibility to cardiac sarcoidosis. Tissue Antigens. 2000;56(1):52–7.PubMedCrossRef
Metadata
Title
The Evolving Landscape of Cutaneous Sarcoidosis: Pathogenic Insight, Clinical Challenges, and New Frontiers in Therapy
Authors
Julie H. Wu
Sotonye Imadojemu
Avrom S. Caplan
Publication date
18-05-2022
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 4/2022
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-022-00693-0

Other articles of this Issue 4/2022

American Journal of Clinical Dermatology 4/2022 Go to the issue

Original Research Article

Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis

Letter to the Editor

Author’s Reply to Pestana et al. Comment on: “Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?”

Original Research Article

Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data

Review Article

Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview

Review Article

Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents

Systematic Review

Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review